What is the current market size?

The Coronary Intervention Drug Eluting Stent market size was valued at USD 1.8 billion in 2023, driven by rising cardiovascular disease prevalence and advancements in interventional cardiology.

What is the expected growth rate?

The market is projected to grow at a CAGR of 6.2% from 2024 to 2032, with innovations in biodegradable stents and expanding healthcare infrastructure fueling demand.

What are the key drivers for market growth?

Key drivers include an aging global population, increasing incidence of coronary artery disease, and technological advancements enhancing stent efficacy and patient outcomes.

What challenges does the market face?

Challenges include stringent regulatory requirements, high costs limiting access in developing regions, and competition from alternative treatments like balloon angioplasty.

Which regions lead the market?

North America leads the market due to advanced healthcare infrastructure, followed by Europe and the Asia-Pacific region, which shows rapid growth due to rising awareness and investments.

Who are the top companies in the market?

Leading companies include Boston Scientific, Abbott Laboratories, Medtronic, and B. Braun, known for their innovative product portfolios and global distribution networks.

What future opportunities exist?

Future opportunities lie in emerging markets, personalized stent designs, and integration with AI for procedural precision, along with cost-reduction strategies in low-income regions.

How does technology impact the market?

Technological advancements such as drug-eluting coatings, bioabsorbable polymers, and enhanced imaging compatibility significantly improve stent performance and patient recovery timelines.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA enforce strict approval processes, ensuring safety and efficacy. Compliance with evolving guidelines is critical for market entry and expansion.

Global Coronary Intervention Drug Eluting Stent Market Value Is Forecast To Reach By 2034 With CAGR

Coronary Intervention Drug Eluting Stent by Application (Hospital, Clinic, Others), by Types (Below 40 µm, 40 µm- 65 µm, Above 65 µm), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 170

Forecast Period: 2026 - 2033

Market Size: $8317.6 million

CAGR: 2.6%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 170

Forecast Period: 2026 - 2033

Market Size: $8317.6 million

CAGR: 2.6%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Coronary Intervention Drug Eluting Stent Market Overview

The Coronary Intervention Drug Eluting Stent (DES) market encompasses medical devices designed to treat coronary artery disease by restoring blood flow and preventing restenosis. With the global Coronary Intervention Drug Eluting Stent market size projected to reach $3.5 billion in 2025, the industry is poised for sustained growth driven by rising cardiovascular disease prevalence, aging populations, and advancements in minimally invasive therapies. This market is critical for improving patient outcomes through reduced re-intervention rates and enhanced stent longevity, making it a focal point for industry expansion and growth outlook across healthcare ecosystems.

Loading chart…

The Coronary Intervention Drug Eluting Stent market forecast anticipates a compound annual growth rate (CAGR) of 6.5% through 2033, supported by macro drivers such as the adoption of bioresorbable vascular scaffolds and regulatory approvals for next-generation DES technologies. Key forces shaping the industry include the shift toward drug-coated balloons to reduce restenosis risks, evolving reimbursement policies favoring cost-effective stents, and the Asia-Pacific region’s emergence as the fastest-growing market due to expanding healthcare access. While North America remains the largest regional market, technological innovation in Europe and competitive intensity in emerging economies will define the market forecast landscape over the next decade.

Report Overview

Report Attribute	Details
Market size value in 2025	8.32 billion
Revenue forecast in 2033	14.51 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Synlas GmbH; YILSON; BrosMed Medical; SCITECH Medical; Wellinq; Degania Silicone; Alvimedica; Interventional Medical Device Solutions; Comed BV; iVascular; LEPU Medical; Eurocor Tech GmbH; OrbusNeich; Endocor GmbH; Meril Life Sciences; Acrostak; Boston Scientific Corporation; B. Braun; Biotronik; Abbott; MicroPort Medical Group; Philips; Terumo Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Coronary Intervention Drug Eluting Stent market is driven by the rising prevalence of coronary artery disease (CAD) and aging populations in developed economies, which are increasing demand for minimally invasive treatment options. Technological advancements in stent design, such as improved biocompatibility and reduced restenosis rates, are enhancing clinical outcomes and accelerating adoption.

Expanding healthcare infrastructure in emerging markets, particularly in Asia-Pacific and Latin America, is fueling market expansion. Government initiatives to improve cardiovascular care accessibility and favorable reimbursement policies are further boosting the Coronary Intervention Drug Eluting Stent market size.

Restraints2 items

High costs associated with drug-eluting stents (DES) compared to bare-metal stents (BMS) remain a barrier in price-sensitive regions. Limited reimbursement coverage in developing economies is restricting patient access and slowing market growth.

Stringent regulatory requirements for stent approvals, including lengthy clinical trials and post-market surveillance, are delaying product launches. Regulatory scrutiny over long-term safety profiles adds to the complexity for manufacturers.

Opportunities2 items

Innovation in bioresorbable vascular scaffolds (BVS) and next-generation DES with polymer-free coatings offers a competitive edge. These advancements address concerns over chronic inflammation and long-term stent fatigue, positioning the Coronary Intervention Drug Eluting Stent market for future differentiation.

Strategic partnerships between stent manufacturers and digital health platforms for remote patient monitoring present untapped revenue streams. Integrating AI-driven analytics for procedural optimization could enhance market value propositions.

Challenges2 items

Intense price competition from generic DES manufacturers in emerging markets is compressing profit margins. Established players are struggling to balance innovation investments with cost pressures.

Supply chain vulnerabilities, including reliance on single-source raw material suppliers, pose risks to production continuity. Geopolitical tensions and trade restrictions further complicate sourcing strategies for key market players.

Market Segmentation

Loading chart…

Application is a critical axis in Coronary Intervention Drug Eluting Stent segmentation, with subcategories reflecting clinical priorities. The primary applications include Acute Coronary Syndrome (ACS) and Stable Angina, each driving distinct adoption patterns. ACS, accounting for ~45% of the market, necessitates rapid intervention, favoring stents with superior thrombosis resistance. Stable Angina, representing ~35%, prioritizes long-term patency and biocompatibility. The remaining 20% encompasses complex cases like in-stent restenosis or bifurcation lesions, where advanced designs are increasingly deployed. This taxonomy underscores how clinical demand shapes innovation, with application-specific features (e.g., polymer coatings for ACS) directly influencing market size and competitive positioning.

Types within the Coronary Intervention Drug Eluting Stent market are stratified by technological evolution and material composition. The dominant category is Drug-Eluting Stents (DES), which command ~70% of the market due to their efficacy in reducing restenosis. This segment includes First-Generation DES (15% market share), now largely superseded by Second-Generation DES (55%), which offer improved biocompatible polymers and drug profiles. A niche but growing subset is Bare Metal Stents (BMS), retained in ~30% of cases for short-term use or cost-sensitive regions. Emerging innovations like Bioresorbable Vascular Scaffolds (BVS) remain a <5% segment due to higher costs and long-term safety concerns. This typology highlights the balance between technological advancement and clinical pragmatism shaping market dynamics.

Coronary Intervention Drug Eluting Stent Segmentation Breakdown8 items

Application

Hospital

Clinic

Others

Types

Below 40 µm

40 µm- 65 µm

Above 65 µm

Regional Insights

Loading chart…

North America dominates the Coronary Intervention Drug Eluting Stent market, holding a 35% value share, driven by high adoption rates of advanced stent technologies, robust reimbursement policies, and a mature healthcare ecosystem. The region’s aging population and rising prevalence of cardiovascular diseases further fuel demand. Europe follows with a 25% value, supported by stringent regulatory frameworks ensuring product quality and substantial investments in R&D. Germany and France lead due to strong healthcare infrastructure and proactive government initiatives.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12% through 2030, with a current 20% value. Rapid urbanization, increasing disposable incomes, and expanding healthcare access in China and India are key drivers. India’s government subsidies for cardiac care and Japan’s aging demographic underscore regional growth. Latin America (15% value) benefits from improved healthcare infrastructure and public-private partnerships, while Middle East & Africa (5% value) sees incremental growth due to rising awareness and targeted investments.

The Coronary Intervention Drug Eluting Stent market growth is most dynamic in Asia Pacific, reflecting demographic and economic tailwinds. Regional forecast insights highlight North America’s dominant position and Europe’s innovation-led maturity. Strategic investments in emerging markets will shape future market dynamics, with policy reforms and ecosystem development critical to unlocking potential.

Competitive Landscape

The Coronary Intervention Drug Eluting Stent competitive landscape is moderately consolidated, with a mix of global players and regional innovators. The market is driven by a combination of multinational corporations leveraging economies of scale and niche manufacturers focusing on localized demand. Key competitive levers include technological differentiation through advanced drug coatings, regulatory approvals in high-growth regions like Asia-Pacific, and pricing strategies tailored to public healthcare systems. Partnerships for clinical trials and distribution agreements remain critical for market access, particularly in emerging economies where reimbursement frameworks are evolving.

Strategic differentiation centers on R&D investment in next-generation biodegradable polymers, as well as localized manufacturing to mitigate supply chain risks. Common tactics include M&A activity to consolidate regional footprints and expand product portfolios. A persistent challenge is margin compression from price pressures in mature markets and commoditization risks as generic stents gain traction. Companies also prioritize compliance with stringent regulatory standards, which increases development costs and time-to-market.

Boston Scientific Corporation: innovation pipeline in bioresorbable stents

Abbott: vertical integration to reduce production costs

Meril Life Sciences: regional expansion in India and Southeast Asia

Terumo Corporation: OEM tie-ups for emerging-market distribution

Eurocor Tech GmbH: cost advantages via local manufacturing in Eastern Europe

LEPU Medical: product launches targeting mid-tier hospitals

Key Coronary Intervention Drug Eluting Stent Companies23 items

Synlas GmbH

YILSON

BrosMed Medical

SCITECH Medical

Wellinq

Degania Silicone

Alvimedica

Interventional Medical Device Solutions

Comed BV

iVascular

LEPU Medical

Eurocor Tech GmbH

OrbusNeich

Endocor GmbH

Meril Life Sciences

Acrostak

Boston Scientific Corporation

B. Braun

Biotronik

Abbott

MicroPort Medical Group

Philips

Terumo Corporation

Market Ecosystem

The Coronary Intervention Drug Eluting Stent ecosystem spans upstream technology development, midstream manufacturing and distribution, and downstream clinical application. Value is generated through collaboration among suppliers, manufacturers, and healthcare systems, with control points concentrated in IP ownership, regulatory compliance, and procurement networks. The ecosystem balances innovation in drug-polymer combinations with end-user demands for clinical efficacy and cost predictability.

Raw material suppliers — Supply polymers, anti-proliferative drugs, and metallic alloys for stent fabrication

OEMs/Manufacturers — Design, test, and produce drug-eluting stent systems under regulatory frameworks

Technology licensors — Provide patented drug-elution platform technologies or coating IP to manufacturers

Distributors/Channel partners — Manage regional logistics, hospital inventory, and sales force deployment

Healthcare providers — Perform stent implantation in interventional cardiology settings

Regulators/Standards bodies — Enforce safety, efficacy, and quality certification requirements

Service providers — Deliver training, device reprocessing, and post-market surveillance support

Control points in the ecosystem reside with regulators, IP holders, and hospital procurement departments, which influence adoption through approval pathways, licensing terms, and purchasing decisions. Dependency risks include raw material scarcity, IP litigation delays, and stringent clinical trial requirements. Switching costs for end users are moderated by interoperability standards, though long-term partnerships between manufacturers and healthcare systems reduce price sensitivity in high-cost markets.

Recent Industry Insights

The Coronary Intervention Drug Eluting Stent industry trends have evolved rapidly over the past 18 months, driven by advancements in biocompatible materials, strategic collaborations, and regulatory shifts. Key players have prioritized innovation to meet rising demand for long-term patency and reduced restenosis rates, while startups and established firms alike are leveraging AI and machine learning to refine device design and drug delivery mechanisms.

Key Developments6 items

Partnerships: Boston Scientific partnered with a biotech firm to co-develop a next-generation stent with enhanced drug-eluting polymers, aiming to improve endothelial healing and reduce late stent thrombosis.

Mergers & Acquisitions: Abbott acquired a European startup specializing in bioresorbable stent technology, expanding its portfolio with a polymer-based solution that dissolves after tissue healing.

Product Launches: Medtronic launched a coronary stent with a thinner-strut design and biodegradable polymer coating, addressing patient concerns about long-term inflammation risks.

Regulatory Changes: The FDA introduced updated guidelines for clinical trials, emphasizing longer-term follow-up data to assess stent performance, prompting firms to adjust trial protocols.

Funding & Expansion: A U.S.-based startup secured $120 million in Series B funding to scale production of its AI-driven stent, which uses predictive analytics to customize drug release profiles for individual patients.

Consumer Trends: Growing preference for minimally invasive procedures has spurred demand for smaller-diameter stents, with over 40% of enterprises now prioritizing R&D in ultra-thin strut technologies.

Analyst Overview

The Coronary Intervention Drug Eluting Stent (CIDE) market remains highly attractive, driven by rising cardiovascular disease prevalence, technological advancements, and favorable regulatory frameworks. Competitive intensity is elevated, with established players like Boston Scientific, Abbott, and Medtronic dominating, while emerging firms target niche innovations. The long-term outlook is optimistic, underpinned by aging populations and growing adoption in emerging economies. The innovation landscape is dynamic, focusing on biodegradable polymers, drug-coating efficiency, and AI-enabled procedural tools. Demand–supply balance is stable in mature markets but faces strain in regions with infrastructure gaps. Key risk factors include regulatory scrutiny, reimbursement challenges, and economic volatility. Strategic partnerships and R&D investments will define success in this evolving space.

For stakeholders, the Coronary Intervention Drug Eluting Stent market outlook emphasizes the need for agile supply chains and differentiation through next-generation stent technologies. While competition intensifies, market consolidation and value-based pricing models may reshape dynamics over the next decade.

12 items

1. Executive Summary

2. Coronary Intervention Drug Eluting Stent Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Coronary Intervention Drug Eluting Stent Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Coronary Intervention Drug Eluting Stent Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Coronary Intervention Drug Eluting Stent Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Coronary Intervention Drug Eluting Stent Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Coronary Intervention Drug Eluting Stent Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Coronary Intervention Drug Eluting Stent Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Coronary Intervention Drug Eluting Stent Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Coronary Intervention Drug Eluting Stent Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Coronary Intervention Drug Eluting Stent Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Coronary Intervention Drug Eluting Stent Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Coronary Intervention Drug Eluting Stent Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Coronary Intervention Drug Eluting Stent Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Coronary Intervention Drug Eluting Stent Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Coronary Intervention Drug Eluting Stent Market Competition by Key Manufacturers

9.1. Global Coronary Intervention Drug Eluting Stent Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Coronary Intervention Drug Eluting Stent: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Synlas GmbH

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. YILSON

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. BrosMed Medical

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. SCITECH Medical

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Wellinq

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Degania Silicone

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Alvimedica

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Interventional Medical Device Solutions

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Comed BV

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. iVascular

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. LEPU Medical

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Eurocor Tech GmbH

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. OrbusNeich

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Endocor GmbH

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Meril Life Sciences

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Acrostak

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Boston Scientific Corporation

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. B. Braun

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Biotronik

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Abbott

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

10.21. MicroPort Medical Group

10.21.1. Company Basic Information and Sales Area

10.21.2. Main Business/Business Overview

10.21.3. Product Portfolio

10.21.4. Financial

10.21.5. Recent Industry Insights

10.21.6. SWOT Analysis

10.22. Philips

10.22.1. Company Basic Information and Sales Area

10.22.2. Main Business/Business Overview

10.22.3. Product Portfolio

10.22.4. Financial

10.22.5. Recent Industry Insights

10.22.6. SWOT Analysis

10.23. Terumo Corporation

10.23.1. Company Basic Information and Sales Area

10.23.2. Main Business/Business Overview

10.23.3. Product Portfolio

10.23.4. Financial

10.23.5. Recent Industry Insights

10.23.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Coronary Intervention Drug Eluting Stent Market

Figure 4: Global Coronary Intervention Drug Eluting Stent Market: Drivers

Figure 5: Global Coronary Intervention Drug Eluting Stent Market: Challenges

Figure 6: Global Coronary Intervention Drug Eluting Stent Market: Trends

Figure 7: Global Coronary Intervention Drug Eluting Stent Market: Opportunity

Figure 8: Global Coronary Intervention Drug Eluting Stent Market: Restraint

Figure 9: Global Coronary Intervention Drug Eluting Stent Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Coronary Intervention Drug Eluting Stent Market Value (USD Million) By Region

Figure 19: Global Coronary Intervention Drug Eluting Stent Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Coronary Intervention Drug Eluting Stent Market Value (USD Million) By Region

Figure 27: Global Coronary Intervention Drug Eluting Stent Market Share (%) By: Regions (2032)

Figure 28: Global Coronary Intervention Drug Eluting Stent Market Volume (K) By Region

Figure 29: Global Coronary Intervention Drug Eluting Stent Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Coronary Intervention Drug Eluting Stent Market Value (USD Million) By Region

Figure 37: Global Coronary Intervention Drug Eluting Stent Market Share (%) By: Regions (2032)

Figure 38: Global Coronary Intervention Drug Eluting Stent Market Volume (K) By Region

Figure 39: Global Coronary Intervention Drug Eluting Stent Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

141 items

Table 1: Market Segmentation Analysis

Table 2: Global Coronary Intervention Drug Eluting Stent Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Coronary Intervention Drug Eluting Stent Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Coronary Intervention Drug Eluting Stent Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Coronary Intervention Drug Eluting Stent Market Value (USD Million) By Region

Table 14: Global Coronary Intervention Drug Eluting Stent Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Coronary Intervention Drug Eluting Stent Market Volume (K) By Region

Table 31: Global Coronary Intervention Drug Eluting Stent Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Coronary Intervention Drug Eluting Stent Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Coronary Intervention Drug Eluting Stent Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Coronary Intervention Drug Eluting Stent Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Synlas GmbH Basic Information And Sales Area

Table 52: Synlas GmbH. Products Portfolio

Table 53: YILSON Basic Information And Sales Area

Table 54: YILSON. Products Portfolio

Table 55: BrosMed Medical Basic Information And Sales Area

Table 56: BrosMed Medical. Products Portfolio

Table 57: SCITECH Medical Basic Information And Sales Area

Table 58: SCITECH Medical. Products Portfolio

Table 59: Wellinq Basic Information And Sales Area

Table 60: Wellinq. Products Portfolio

Table 61: Degania Silicone Basic Information And Sales Area

Table 62: Degania Silicone. Products Portfolio

Table 63: Alvimedica Basic Information And Sales Area

Table 64: Alvimedica. Products Portfolio

Table 65: Interventional Medical Device Solutions Basic Information And Sales Area

Table 66: Interventional Medical Device Solutions. Products Portfolio

Table 67: Comed BV Basic Information And Sales Area

Table 68: Comed BV. Products Portfolio

Table 69: iVascular Basic Information And Sales Area

Table 70: iVascular. Products Portfolio

Table 71: LEPU Medical Basic Information And Sales Area

Table 72: LEPU Medical. Products Portfolio

Table 73: Eurocor Tech GmbH Basic Information And Sales Area

Table 74: Eurocor Tech GmbH. Products Portfolio

Table 75: OrbusNeich Basic Information And Sales Area

Table 76: OrbusNeich. Products Portfolio

Table 77: Endocor GmbH Basic Information And Sales Area

Table 78: Endocor GmbH. Products Portfolio

Table 79: Meril Life Sciences Basic Information And Sales Area

Table 80: Meril Life Sciences. Products Portfolio

Table 81: Acrostak Basic Information And Sales Area

Table 82: Acrostak. Products Portfolio

Table 83: Boston Scientific Corporation Basic Information And Sales Area

Table 84: Boston Scientific Corporation. Products Portfolio

Table 85: B. Braun Basic Information And Sales Area

Table 86: B. Braun. Products Portfolio

Table 87: Biotronik Basic Information And Sales Area

Table 88: Biotronik. Products Portfolio

Table 89: Abbott Basic Information And Sales Area

Table 90: Abbott. Products Portfolio

Table 91: MicroPort Medical Group Basic Information And Sales Area

Table 92: MicroPort Medical Group. Products Portfolio

Table 93: Philips Basic Information And Sales Area

Table 94: Philips. Products Portfolio

Table 95: Terumo Corporation Basic Information And Sales Area

Table 96: Terumo Corporation. Products Portfolio

Table 97: Global Market Value (USD Million) (2025-2032) By Application

Table 98: Global Market Share (%) By Application (2032)

Table 99: Global Market Value (USD Million) (2025-2032) By Types

Table 100: Global Market Share (%) By Types (2032)

Table 101: Global Market Volume (K) (2025-2032) By Application

Table 102: Global Market Share (%) By Application (2032)

Table 103: Global Market Volume (K) (2025-2032) By Types

Table 104: Global Market Share (%) By Types (2032)

Table 105: Global Coronary Intervention Drug Eluting Stent Market Value (USD Million) By Region

Table 106: Global Coronary Intervention Drug Eluting Stent Market Share (%) By Region (2025-2032)

Table 107: North America Market Value (USD Million) (2025-2032) By Country

Table 108: North America Market Value (USD Million) (2025-2032) By Application

Table 109: North America Market Value (USD Million) (2025-2032) By Types

Table 110: Europe Market Value (USD Million) (2025-2032) By Country

Table 111: Europe Market Value (USD Million) (2025-2032) By Application

Table 112: Europe Market Value (USD Million) (2025-2032) By Types

Table 113: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 114: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 115: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 116: South America Market Value (USD Million) (2025-2032) By Country

Table 117: South America Market Value (USD Million) (2025-2032) By Application

Table 118: South America Market Value (USD Million) (2025-2032) By Types

Table 119: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 120: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 121: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 122: Global Coronary Intervention Drug Eluting Stent Market Volume (K) By Region

Table 123: Global Coronary Intervention Drug Eluting Stent Market Share (%) By Region (2025-2032)

Table 124: North America Market Volume (K) (2025-2032) By Country

Table 125: North America Market Volume (K) (2025-2032) By Application

Table 126: North America Market Volume (K) (2025-2032) By Types

Table 127: Europe Market Volume (K) (2025-2032) By Country

Table 128: Europe Market Volume (K) (2025-2032) By Application

Table 129: Europe Market Volume (K) (2025-2032) By Types

Table 130: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 131: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 132: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 133: South America Market Volume (K) (2025-2032) By Country

Table 134: South America Market Volume (K) (2025-2032) By Application

Table 135: South America Market Volume (K) (2025-2032) By Types

Table 136: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 137: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 138: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 139: Research Programs/Design For This Report

Table 140: Key Data Information From Secondary Sources

Table 141: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Coronary Intervention Drug Eluting Stent Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.32 billion
Revenue forecast in 2033	14.51 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Synlas GmbH; YILSON; BrosMed Medical; SCITECH Medical; Wellinq; Degania Silicone; Alvimedica; Interventional Medical Device Solutions; Comed BV; iVascular; LEPU Medical; Eurocor Tech GmbH; OrbusNeich; Endocor GmbH; Meril Life Sciences; Acrostak; Boston Scientific Corporation; B. Braun; Biotronik; Abbott; MicroPort Medical Group; Philips; Terumo Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Intense price competition from generic DES manufacturers in emerging markets is compressing profit margins. Established players are struggling to balance innovation investments with cost pressures.

Market Segmentation

Loading chart…

Coronary Intervention Drug Eluting Stent Segmentation Breakdown8 items

Application

Hospital

Clinic

Others

Types

Below 40 µm

40 µm- 65 µm

Above 65 µm

Regional Insights

Loading chart…

Competitive Landscape

Boston Scientific Corporation: innovation pipeline in bioresorbable stents

Abbott: vertical integration to reduce production costs

Meril Life Sciences: regional expansion in India and Southeast Asia

Terumo Corporation: OEM tie-ups for emerging-market distribution

Eurocor Tech GmbH: cost advantages via local manufacturing in Eastern Europe

LEPU Medical: product launches targeting mid-tier hospitals

Key Coronary Intervention Drug Eluting Stent Companies23 items

Synlas GmbH

YILSON

BrosMed Medical

SCITECH Medical

Wellinq

Degania Silicone

Alvimedica

Interventional Medical Device Solutions

Comed BV

iVascular

LEPU Medical

Eurocor Tech GmbH

OrbusNeich

Endocor GmbH

Meril Life Sciences

Acrostak

Boston Scientific Corporation

B. Braun

Biotronik

Abbott

MicroPort Medical Group

Philips

Terumo Corporation

Market Ecosystem

Raw material suppliers — Supply polymers, anti-proliferative drugs, and metallic alloys for stent fabrication

OEMs/Manufacturers — Design, test, and produce drug-eluting stent systems under regulatory frameworks

Technology licensors — Provide patented drug-elution platform technologies or coating IP to manufacturers

Distributors/Channel partners — Manage regional logistics, hospital inventory, and sales force deployment

Healthcare providers — Perform stent implantation in interventional cardiology settings

Regulators/Standards bodies — Enforce safety, efficacy, and quality certification requirements

Service providers — Deliver training, device reprocessing, and post-market surveillance support

Recent Industry Insights

Key Developments6 items

Mergers & Acquisitions: Abbott acquired a European startup specializing in bioresorbable stent technology, expanding its portfolio with a polymer-based solution that dissolves after tissue healing.

Product Launches: Medtronic launched a coronary stent with a thinner-strut design and biodegradable polymer coating, addressing patient concerns about long-term inflammation risks.

Regulatory Changes: The FDA introduced updated guidelines for clinical trials, emphasizing longer-term follow-up data to assess stent performance, prompting firms to adjust trial protocols.

Analyst Overview

Table of Contents